search button
Open Access

Association between XRCC1 and ERCC1 single‑nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma

  • Authors:
    • Xue Huang
    • Changmin Liu
    • Yayun Cui
    • Heping Zhang
    • Yongping Liu
    • Xifa Zhou
    • Judong Luo

  • View Affiliations

  • Published online on: December 14, 2016     https://doi.org/10.3892/ol.2016.5496
  • Pages: 704-714

  • Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the association between single‑nucleotide polymorphisms (SNPs) in X‑ray repair cross‑complementing 1‑399 (XRCC1‑399) or excision repair cross‑complementation group 1‑118 (ERCC1‑118) and the short‑term efficacy of radiochemotherapy, tumor metastasis and relapse, as well as the survival time in patients with esophageal squamous cell carcinoma (ESCC). TaqMan probe‑based quantitative polymerase chain reaction (qPCR) was conducted to examine the levels of XRCC1‑399 and ERCC1‑118 SNPs in the peripheral blood of 50 patients with pathologically confirmed ESCC. In addition, the associations between different genotypes and short‑term therapeutic efficacy [the complete remission (CR) rate], tumor metastasis and relapse, as well as the survival time following concurrent radiochemotherapy, were determined. A total of 50 ESCC patients who received concurrent radiochemotherapy were enrolled. It was found that the short‑term therapeutic efficacy (CR rate) was higher in the group of patients carrying the homozygous mutation of XRCC1‑399 (A/A genotype) than in the group of patients without the XRCC1‑399 mutation (G/G genotype). In addition, the CR rate was significantly increased in patients carrying one or two ERCC1‑118 C alleles (C/C or C/T genotype) compared with patients lacking the C allele (T/T genotype). The differences were statistically significant (A/A vs. G/G, P=0.014; TT vs. C/T+C/C, P=0.040). During the follow‑up period, the group of patients carrying the homozygous mutation of XRCC1‑399 (A/A genotype) exhibited a markedly reduced risk of metastasis and relapse compared with the group of patients carrying non‑mutated XRCC1‑399 (G/G genotype; P=0.031). By contrast, ERCC1‑118 SNP was not associated with the risk of metastasis and recurrence (P>0.05). The combined results of univariate and multivariate Cox regression analysis showed that the SNP in ERCC1‑118 was closely associated with survival time. The mean survival time was significantly prolonged in patients carrying 1 or 2 C alleles (C/C or C/T genotype) compared with patients lacking the C allele (T/T genotype) [T/T vs. C/C, HR=12.96, 95% confidence interval (CI)=3.08‑54.61, P<0.001; TT vs. C/T+C/C, HR=11.71, 95% CI=3.06‑44.83, P<0.001]. However, XRCC1‑399SNP had no effect on survival time (P>0.05). XRCCl‑399 SNP was associated with the short‑term therapeutic efficacy (the CR rate) and tumor metastasis/relapse in ESCC patients who received the docetaxel plus cisplatin (TP) regimen‑based concurrent radiochemotherapy. By contrast, ERCC1‑118 SNP was significantly associated with the short‑term therapeutic efficacy (the CR rate) and survival time in ESCC patients who received TP regimen‑based concurrent radiochemotherapy.
View Figures
View References

Related Articles

Journal Cover

February-2017
Volume 13 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Huang X, Liu C, Cui Y, Zhang H, Liu Y, Zhou X and Luo J: Association between XRCC1 and ERCC1 single‑nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma. Oncol Lett 13: 704-714, 2017
APA
Huang, X., Liu, C., Cui, Y., Zhang, H., Liu, Y., Zhou, X., & Luo, J. (2017). Association between XRCC1 and ERCC1 single‑nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma. Oncology Letters, 13, 704-714. https://doi.org/10.3892/ol.2016.5496
MLA
Huang, X., Liu, C., Cui, Y., Zhang, H., Liu, Y., Zhou, X., Luo, J."Association between XRCC1 and ERCC1 single‑nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma". Oncology Letters 13.2 (2017): 704-714.
Chicago
Huang, X., Liu, C., Cui, Y., Zhang, H., Liu, Y., Zhou, X., Luo, J."Association between XRCC1 and ERCC1 single‑nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma". Oncology Letters 13, no. 2 (2017): 704-714. https://doi.org/10.3892/ol.2016.5496